In late 2011, a year after swine flu outbreaks in India, three vaccine manufacturers were contracted for nearly two million doses of H1N1 vaccine to the government. Serum Institute of India, Bharat Biotech and Panacea Biotec had obtained licenses for their products the previous year, invested in new plants and were all set to supply the doses. For the paediatric vaccine makers, this was the first big step towards adult vaccines and a whole new market. Today, those expired doses are dumped in warehouses. The plants lay idle as the companies await closure of an arbitration with the ministry of health.

Cut to February 2017.

Shoot influenza out with Portea. Take a flu shot and protect your family. More you protect, More you save. Book now and save up to 50% on family vaccination packages. To book call 1800…”.

It’s a text message from a home healthcare company. A direct-to-consumer sell no doubt, but also indicative of the fact that seasonal flu shots, for long a practice in the developed world against influenza, have arrived in India. Even if that means paying out of pocket, unlike many other countries where payers reimburse seasonal flu shots. The French drugmaker Sanofi Pasteur, which has been selling influenza vaccines in India for a decade, says the acceptance has increased in the last few years, leading to the doubling of vaccination numbers. Sanofi and others sold two million doses last year. People are now open to vaccination because sporadic flu outbreaks throw life out of gear. Like the one Tamil Nadu is currently facing and where flu vaccine stocks are being rushed creating artificial shortages in cities like Bengaluru.

Did the Indian vaccine makers, which supply 60% of the global paediatric vaccines, dump their pandemic flu plans too soon?

For all the three manufacturers, the H1N1 contract was meant to propel them into flu vaccines eventually. It turned out to be a ‘jam’. “We thought pandemic preparedness would run into billions of doses and would give us revenue to get into seasonal flu, chest infection, and similar other vaccines. But we got demotivated when the orders were arbitrarily cancelled,” says Rajesh Jain, joint managing director of Panacea.

Missed opportunity, messier experience

In April 2009, the first case of influenza A H1N1 was detected in Mexico and by year-end, 214 countries were affected by the pandemic. (Flu viruses are of three broad categories—influenza A, B or C. Of this, influenza A is the most common type. H1N1 is a variety of influenza A and has many different strains.) By May 2010, while the WHO declared the pandemic to be over, India took it seriously and made some “unprecedented and innovative interventions”.

AUTHOR

Seema Singh

Seema has over two decades of experience in journalism. Before starting The Ken, Seema wrote “Myth Breaker: Kiran Mazumdar-Shaw and the Story of Indian Biotech”, published by HarperCollins in May 2016. Prior to that, she was a senior editor and bureau chief for Bangalore with Forbes India, and before that she wrote for Mint. Seema has written for numerous international publications like IEEE-Spectrum, New Scientist, Cell and Newsweek. Seema is a Knight Science Journalism Fellow from the Massachusetts Institute of Technology and a MacArthur Foundation Research Grantee.

View Full Profile

Available exclusively to subscribers of The Ken India

This story is a part of The Ken India edition. Subscribe. Questions?

MOST POPULAR

Annual Subscription

12-month access to 200+ stories, archive of 800+ stories from our India edition. Plus our premium newsletters, Beyond The First Order and The Nutgraf worth Rs. 99/month or $2/month each for free.

Rs. 2,750

Subscribe
 

Quarterly Subscription

3-month access to 60+ new stories with 3-months worth of archives from our India edition. Plus our premium newsletters, Beyond The First Order and The Nutgraf worth Rs. 99/month or $2/month each for free.

Rs. 1,750

Subscribe
 

Single Story

Instant access to this story for a year along with comment privileges.

Rs. 500

Subscribe
MOST POPULAR

Annual Subscription

12-month access to 150+ stories from Southeast Asia.

$ 120

Subscribe
 

Quarterly Subscription

3-month access to 35+ stories from Southeast Asia.

$ 50

Subscribe
 

Single Story

Instant access to this story for a year along with comment privileges.

$ 20

Subscribe

Questions?

What is The Ken?

The Ken is a subscription-only business journalism website and app that provides coverage across two editions - India and Southeast Asia.

What kind of stories do you write?

We publish sharp, original and reported stories on technology, business and healthcare. Our stories are forward-looking, analytical and directional — supported by data, visualisations and infographics.

We use language and narrative that is accessible to even lay readers. And we optimise for quality over quantity, every single time.

What do I get if I subscribe?

For subscribers of the India edition, we publish a new story every weekday, a premium daily newsletter, Beyond The First Order and a weekly newsletter - The Nutgraf.

For subscribers of the Southeast Asia edition, we publish a new story three days a week and a weekly newsletter, Strait Up.

The annual subscription will get you complete, exclusive access to our archive of previously published stories for your edition, along with access to our subscriber-only mobile apps, our premium comment sections, our newsletter archives and several other gifts and benefits.

Do I need to pay separately for your premium newsletters?

Nope. Paid, premium subscribers of The Ken get our newsletters delivered for free.

Does a subscription to the India edition grant me access to Southeast Asia stories? Or vice-versa?

Afraid not. Each edition is separate with its own subscription plan. The India edition publishes stories focused on India. The Southeast Asia edition is focused on Southeast Asia. We may occasionally cross-publish stories from one edition to the other.

Do you offer an all-access joint subscription for both editions?

Not yet. If you’d like to access both editions, you’ll have to purchase two subscriptions separately - one for India and the other for Southeast Asia.

Do you offer any discounts?

No. We have a zero discounts policy.

Is there a free trial I can opt for?

We don’t offer any trials, but you can sign up for a free account which will give you access to the weekly free story, our archive of free stories and summaries of the paid stories. You can stay on the free account as long as you’d like.

Do you offer refunds?

We allow you to sample our journalism for free before signing up, and after you do, we stand by its quality. But we do not offer refunds.

I am facing some trouble purchasing a subscription. What can I do?

Please write to us at [email protected] detailing the error or queries.